Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 23;17(1):124.
doi: 10.1186/s13019-022-01871-1.

Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

Joanna R Rock  1   2 , Cynthia A Kos  3 , Anthony Lemaire  3   4 , Hirohisa Ikegami  3   4 , Mark J Russo  3   4 , Danyaal Moin  3   4 , Kenneth Dulnuan  3   4 , Deepa Iyer  3   4
Affiliations

Single center first year experience and outcomes with Impella 5.5 left ventricular assist device

Joanna R Rock et al. J Cardiothorac Surg. .

Abstract

Background: The Impella 5.5® was approved by the FDA for use for mechanical circulatory support up to 14 days in late 2019 at limited centers in the United States. Our single center's experience with Impella 5.5® can expand the overall understanding for achieving successful patient outcomes as well as provide support for the expansion of its FDA-approved use.

Methods: This study is an IRB-approved single-center retrospective cohort analysis of hospitalized adult patient characteristics and outcomes in cases where the Impella 5.5® was utilized for mechanical circulatory support.

Results: A total of 26 implanted Impella 5.5® devices were identified in 24 hospitalized patients at our institution from January 2020 to January 2021. The overall survival rate during index hospitalization was 75%. Eleven Impella 5.5® devices were identified in 10 patients with an average device implantation greater than 14 days. Average device implantation for this subgroup was 27 days with a range of 15-80 days. Survival rate for Impella 5.5® use greater than 14 days was 67%. In the entire cohort and subgroup of device implantation > 14 days, evidence of end organ damage improved with Impella 5.5® use. Complications in our cohort and subgroup of device implantation > 14 days were similar to previously reported complication incidence of axillary inserted LVAD devices.

Conclusions: Our institution's experience with the Impella 5.5® has been strongly positive with favorable outcomes and helps to establish the Impella 5.5® as a viable option for mechanical circulatory support beyond 14 days.

Keywords: Advanced heart failure; Cardiogenic shock; Cardiomyopathy; Impella; Left ventricular assist devices; Mechanical circulatory support.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
General laboratory values for entire cohort. Trends in laboratory values show improvement in kidney and liver function with Impella 5.5 use. Hemoglobin and platelet both show an initial decrease after implantation with stabilization at time of explant
Fig. 2
Fig. 2
General laboratory values for patients with implantation > 14 days. Trends in laboratory values show improvement in kidney and liver function with Impella 5.5 use for > 14 days. Liver enzymes first worsened in the 24 h after implant after stabilization and improvement with time. Hemoglobin and platelet both show an initial decrease after implantation with stabilization at time of explant
See this image and copyright information in PMC

References

    1. Castro L, Krause L, Reichenspurner H, Bernhardt A. Worldwide gender differences during mechanical circulatory support: an analysis of the international society for heart and lung transplantation mechanically assisted circulatory support registry data. J Heart Lung Transpl. 2020;39(4):S107–S108. doi: 10.1016/j.healun.2020.01.970. - DOI
    1. Chair SY, Yu DS, Ng MT, et al. Evolvement of left ventricular assist device: the implications on heart failure management. J Geriatr Cardiol. 2016;13(5):425–430. doi: 10.11909/j.issn.1671-5411.2016.05.015. - DOI - PMC - PubMed
    1. Batsides G, Massaro J, Cheung A, Soltesz E, Ramzy D, Anderson MB. Outcomes of Impella 5.0 in cardiogenic shock: a systematic review and meta-analysis. Innovations. 2018;13(4):254–260. doi: 10.1097/IMI.0000000000000535. - DOI - PubMed
    1. Lemaire A, Anderson MB, Lee LY, et al. The Impella device for acute mechanical circulatory support in patients in cardiogenic shock. Ann Thorac Surg. 2014;97(1):133–138. doi: 10.1016/j.athoracsur.2013.07.053. - DOI - PubMed
    1. Rihal CS, Naidu SS, Givertz MM, et al. 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care. J Am Coll Cardiol. 2015;65(19):2140–2141. doi: 10.1016/j.jacc.2015.02.043. - DOI - PubMed

LinkOut - more resources